Pregabalin Capsule
Product Images NDC 71610-926

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71610-926). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 0926 30)

Pregabalin 200 mg oral capsules, packaged in a container of 30. The label includes storage instructions to keep between 20-25 degrees Celsius, mentions the product is for prescription use only, and warns that it may be habit-forming. The labeler is Aphena Pharma Solutions - Tennessee, LLC, with packaging location in Cookeville, TN.*

FDA Label Image

Aphena (Aphena)

FDA Label Image

Chemical Structure (Pregabalin 01)

Chemical structure of the active ingredient Pregabalin, showing its molecular configuration with characteristic amino and carboxyl groups.*

FDA Label Image

Figure 1 (Pregabalin 02)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin at 25 mg, 100 mg, and 200 mg three times a day, and placebo. The graph illustrates dose-dependent effects with Pregabalin groups generally showing higher patient improvement than placebo.*

FDA Label Image

Figure 2 (Pregabalin 03)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline. Two lines represent Pregabalin 100 mg three times a day and placebo, showing distinct trends in patient improvement across varying pain improvement percentages.*

FDA Label Image

Figure 3 (Pregabalin 04)

A line graph showing the percent of patients improved plotted against percent improvement in pain from baseline. Four lines represent Pregabalin dosed at 300 mg, 150 mg, and 75 mg twice a day, and a placebo. The graph compares the efficacy of different doses versus placebo in pain improvement.*

FDA Label Image

Figure 4 (Pregabalin 05)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and Placebo. The graph shows a higher percentage of patient improvement for Pregabalin 200 mg compared to the other groups across the range of pain improvement percentages.*

FDA Label Image

Figure 5 (Pregabalin 06)

A line graph comparing percent improvement in pain from baseline (X-axis) against percent of patients improved (Y-axis) for Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. Three lines show different response rates, with labels for each treatment group.*

FDA Label Image

Figure 6 (Pregabalin 07)

A bar chart presenting responder rates (%) from two studies, Study E1 and Study E3. The horizontal axis shows treatment groups including placebo and varying dosages (100 mg/day to 600 mg/day). The vertical axis indicates responder rate percentages. Sample sizes (N) are listed below each bar. The chart includes a note that some results are statistically significant compared to placebo.*

FDA Label Image

Figure 7 (Pregabalin 08)

A line chart showing the median percentage change from baseline in seizure reduction versus dose in mg/day. Four datasets are plotted from different studies (E1 BD, E2 TID, E3 BD, E3 TID) with significant p-values indicated for dose points up to 600 mg/day. The placebo dose is marked at zero, and all data points show increasing seizure reduction with dose.*

FDA Label Image

Figure 8 (Pregabalin 09)

Bar graph showing responder rates (%) for three groups: Placebo (22.6%, N=93), 2.5 mg/kg/day dose (29.1%, N=103), and 10 mg/kg/day dose (40.6%, N=96). The vertical axis represents responder rate percentage, and the horizontal axis specifies the treatment groups.*

FDA Label Image

Figure 9 (Pregabalin 10)

A line graph depicting Percent Improvement in Pain from Baseline versus Percent of Patients Improved. Four lines represent Pregabalin 600mg daily dose, 450mg daily dose, 300mg daily dose, and placebo, showing comparison of patient improvement rates across doses.*

FDA Label Image

Figure 10 (Pregabalin 11)

A line graph depicting the estimated percentage of subjects without LTR over a 180-day period, comparing Pregabalin to placebo. The graph shows two lines: a solid line for Pregabalin and a dashed line for placebo, indicating different trends in subject outcomes over time.*

FDA Label Image

Figure 11 (Pregabalin 12)

A line graph showing the percent of subjects improved on the vertical axis and percent improved from baseline to week 12 BOCF on the horizontal axis. It compares Pregabalin and Placebo, with Pregabalin represented by a solid line and Placebo by a dotted line, illustrating higher improvement percentages for Pregabalin across the range.*

FDA Label Image

Figure 12 (Pregabalin 13)

A comparative line graph showing the percent of subjects improved on the vertical axis versus percent improvement from baseline to Week 16 BOCF on the horizontal axis. The graph compares Pregabalin and placebo, with Pregabalin showing a consistently higher percentage of subjects improved across the range compared to placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.